Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD

Comprehensive Therapy

Volumn 23, Issue 5, 1997, Pages 327-331

  Rothschild, Bruce ^a,b   Yakubov, Lyn E ^c  

^a ARTHRITIS CENTER OF NORTHEAST OHIO   (United States)

^b Northeastern Ohio Medical University   (United States)

^c NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PYROPHOSPHATE; CORTICOSTEROID; GLYCOSAMINOGLYCAN POLYSULFATE; HYDROXYCHLOROQUINE; MAGNESIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; YTTRIUM 90;

ADULT; AGED; ARTHRITIS; CALCINOSIS; CHONDROCALCINOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CRYOTHERAPY; DIATHERMY; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTHERMIC THERAPY; INTRAARTICULAR DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PSEUDOGOUT; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; ULTRASOUND THERAPY;

AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; CHONDROCALCINOSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0030982171     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Markel SF, Hart WR. Arthropathy in calcium pyrophosphate dihydrate crystal deposition disease. Arch Pathol. 1982;106: 529-533.
2. Rothschild BM, Woods RJ, Rothschild C. Calcium pyrophosphate deposition disease: description in defleshed skeletons. Clin Exp Rheumatol. 1992;10:557-564.
3. Resnick D, Niwayama G. Diagnosis of Bone and Joint Disorders. Philadelphia, PA: W.B. Saunders; 1988.
4. Rothschild BM. Rheumatology: A Primary Care Approach. New York, NY: Yorke Medical Press; 1982.
5. McCarthy DJ. The heberden oration. 1982: crystals, joints and consternation. Ann Rheumatic Dis. 1983;42:243-253.
6. Menkes CJ, Simon F, Delrieu F, et al. Destructive arthropathy in chondrocalcinosis articularis. Arthritis Rheum. 1976;19:329-348.
7. Pritzker KP, Phillips H, Luk SG, et al. Pseudotumor of tempo romandibular joint: destructive calcium pyrophosphate dihydrate arthropathy. J Rheumatol 1976;3:70-81.
8. Rothschild BM, Martin L. Paleopathology: Disease in the Fossil Record. London, England: CRC Press; 1993.
9. Yosipovitch ZH, Glimcher MJ. Articular chondrocalcinosis, hydroxyapatite deposition disease, in adult mature rabbits. J Bone Jt Surg. 1972;54a:841-853.
10. McCarthy DJ. Diagnostic mimicry in arthritis patterns of joint involvement associated with calcium pyrophosphate dihydrate crystal deposits. Bull Rheumatic Dis. 1975;25:804-809.
11. Currey HL. Pyrophosphate arthropathy and calcific periarthritis. Clin Orthop Rel Res. 1970;71:70-80.
12. Gerster JC, Vischer TL, Fallet GH. Destructive arthropathy in generalized osteoarthritis with articular chondrocalcinosis. J Rheumatol. 1975;2:265-269.
13. Richards AJ, Hamilton EB. Destructive arthropathy in chondrocalcinosis articularis. Ann Rheumatic Dis. 1974;33:196-203.
14. Richards AJ, Hamilton EB. Spinal changes in idiopathic chondrocalcinosis articularis. Rheumatol Rehab. 1976;15:138-142.
15. Robinson RG. Calcium pyrophosphate crystal synovitis with articular chondrocalcinosis. Rheumatology. 1971;1:153-164.
16. Villiaumey J, Larget-Piet B, di Menza C, et al. Caracteres symptomatiques et evolutifs des destructions articulaires observes au cours de la chondrocalcinose. Rev Rhum. 1975;42:263-273.
17. Doherty M, Dieppe PA. Double-blind, placebo-controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Ann Rheumatic Dis. 1983;42(suppl):106-107.
18. Doherty M, Dieppe PA. Effect of intra-articular yttrium-90 on chronic pyrophosphate arthropathy of the knee. Lancet. 1983; 2:1243-1245.
19. Sarkozi AM, Nemeth-Csoka M, Bartosiewicz G. Effects of glyco saminoglycan polysulphate in the treatment of chondrocalcinosis. Clin Exp Rheumatol. 1988;6:3-8.
20. Resnick CS, Resnick D. Crystal deposition disease. Semin Arthritis Rheum. 1983;12:390-403.
21. McCarthy DJ. Calcium pyrophosphate dihydrate crystal deposition disease. 1975. Arthritis Rheum. 1976;19:275-285.
22. McCarthy DJ. Arthritis and Allied Conditions. 11th ed. Philadelphia, PA: Lea & Febiger; 1989.
23. Burt HM, Jackson JK, Rowel J. Calcium pyrophosphate and monosodium urate crystal interactions with neutrophils: effect of crystal size and lipoprotein binding to crystals. J Rheumatol. 1989;16:809-817.
24. Cheung HS, Story MT, McCarthy DJ. Mitogenic effects of hydroxyapatite and calcium pyrophosphate dihydrate crystals on cultured mammalian cells. Arthritis Rheum. 1984;27:668-674.
25. Kharazmi A, Valerius NH, Hoiby N. Effect of antimalarial drugs on human neutrophil chemotaxis in vitro. Acta Path Microbiol Immunol Scand. 1983;91(Section C):293-298.
26. Koranda FC. Antimalarials. J Amer Acad Dermatol 1981;4:650-655.
27. Prowse C, Pepper D, Dawes J. Prevention of the platelet alpha-granule release reaction by membrane active drugs. Thrombosis Res. 1982;25:219-227.
28. Dennis PA, Aronson NN Jr. The effects of low temperature and chloroquine on 125i-insulin degradation by the perfused rat liver. Arch Biochem Biophys. 1981;212:170-176.
29. Quatraro A, Consoli G, Magno M, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus: a new job for an old drug? Ann Intern Med. 1990;112:678-681.
30. Genant HK. Roentgenographic aspects of calcium pyrophosphate dihydrate crystal deposition disease (pseudogout). Arthritis Rheum. 1976;19:307-328.
31. Resnick D, Pineda C. Vertebral involvement in calcium pyrophosphate dihydrate crystal deposition disease. Radiology. 1984;153:55-60.
32. Rothschild BM, Woods RJ. Osteoarthritis, calcium pyrophosphate deposition disease, and osseous infection in old world primates. Amer J Phys Anthropol. 1992;87:341-347.
33. Bunch TW, O'Duffy JD, Tomkins RB, et al. Controlled trial of hydroxychloroquine and d-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum. 1984; 27:267-276.
34. Morsman CD, Livesley SJ, Richards IM, et al. Screening for hydroxychloroquine retinal toxicity: is it necessary? Eye. 1990;4:572-576.
35. Mackenzie AH, Scherbel AL. Chloroquine and hydroxychloroquine in rheumatological therapy. Clin Rheumatic Dis. 1980;6:545-566.
36. Hurst NP, French JK, Gorjatschko L, et al. Chloroquine and hydroxychloroquine inhibit multiple sites in metabolic pathways leading to neutrophil superoxide release. J Rheumatol. 1988;15:23-27.
37. Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum. 1987;16:206-221.